COMMUNIQUÉS West-GlobeNewswire

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
11/02/2026
-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. [...]
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
11/02/2026
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally supported [...]
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
11/02/2026
BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will [...]
Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota
11/02/2026
The appointment of former General Manager of Novo Nordisk UK follows the recent appointment of Professor Sir Jonathan Van-Tam to Reset Health’s Advisory Board LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the [...]
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
11/02/2026
Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy product Partnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 [...]
InfiniHealth Medical Group Announces Integrated Multispecialty Care Model to Support Coordinated Specialty Services Across New Jersey
11/02/2026
WEST ORANGE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- InfiniHealth Medical Group today announced the continued advancement of its integrated multispecialty care model, a clinical framework that brings multiple board- [...]
Galecto Announces Pricing of $275 Million Underwritten Public Offering
11/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
11/02/2026
TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
Berlin Protocol Performance Enhancer Product Information Updated — What Do Consumers Consider When Researching Male Enhancement Supplement Options in 2026?
11/02/2026
An informational overview examining what consumers research about Berlin Protocol Performance Enhancer, ingredient transparency in the male enhancement supplement category, and what publicly available product [...]
Galapagos Receives Transparency Notifications from Bank of America
10/02/2026
Mechelen, Belgium ; February 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation [...]
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
10/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
10/02/2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Picard Medical/ SynCardia to Present at European Mechanical Circulatory Support Summit and International Course on Mechanical Circulatory Support and New Technologies in Heart Failure
10/02/2026
TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved [...]
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
10/02/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Feb. 10, [...]
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
10/02/2026
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year [...]
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced [...]
PetVivo Issues Correction and Replacement Press Release; Sets Fiscal Third Quarter 2026 Conference Call for Tuesday, February 17, 2026 at 5:00 p.m. ET
10/02/2026
MINNEAPOLIS, MN, US, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., in collaboration with its wholly-owned subsidiary PetVivo Animal Health (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering [...]
The Cooperative of American Physicians Announces Continued A+ (Superior) Rating for the Mutual Protection Trust
10/02/2026
Rating reaffirmed for the 19th consecutive year, reflecting long-term financial stability LOS ANGELES, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The Cooperative of American Physicians, Inc. (CAP) announced that AM Best has [...]
DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et discutera de l'avenir de l'EPIT lors du congrès annuel 2026 de l'AAAAI
10/02/2026
Châtillon, France, le 10 février (22 :30 CET) 2026 DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et [...]

Pages